Mode
Text Size
Log in / Sign up

Patient Questions

Real questions from health communities, answered with cited research from PubMed and Vellito's article corpus. Plain language, no medical advice. How this works.

Oncology

How does innate immune recognition affect the progression of Cervical Cancer and HPV?

HPV evades innate immune detection by suppressing PRR signaling and NLRP3 inflammasome, enabling persistent infection and cervical cancer progression.

Oncology

Does EGCG have therapeutic effects on digestive system diseases like Esophageal Cancer?

EGCG shows promise against esophageal cancer in lab and animal studies, and a human trial found it reduced radiation-induced esophagitis, but more clinical research is needed.

Oncology

Does conversion surgery improve survival rates for patients with cT4 Esophageal Cancer?

Yes, conversion surgery after induction therapy significantly improves survival for cT4 esophageal cancer, with 5-year survival of 26.5% vs 11.6% for definitive therapy alone.

Oncology

Do older age or other health issues increase complications after surgery for Esophageal Cancer?

While older age and other health issues are often associated with higher risks in open surgeries, research suggests they may not increase the risk of severe complications for…

Oncology

Can relacorilant and nab-paclitaxel help patients with platinum-resistant Ovarian Cancer?

Yes, relacorilant plus nab-paclitaxel improves survival in platinum-resistant ovarian cancer, based on phase 2 and phase 3 trial results.

Oncology

Do PARP inhibitors improve survival for patients with BRCA-mutated Ovarian Cancer?

Yes, PARP inhibitors significantly improve progression-free survival for patients with BRCA-mutated ovarian cancer, with some studies also showing overall survival benefits.

Oncology

Is [68Ga]Ga-FAPI PET imaging accurate for diagnosing Ovarian Cancer?

Yes, [68Ga]Ga-FAPI PET imaging is highly accurate for diagnosing ovarian cancer, especially for detecting peritoneal and lymph node metastases, and may outperform standard FDG…

Oncology

What is the focus of current clinical trials for Non-Hodgkin's Lymphoma?

Current clinical trials for non-Hodgkin's lymphoma (NHL) focus heavily on early-phase development of CAR-T cell therapies and the evaluation of bispecific antibodies.

Oncology

Does adding gemcitabine improve survival for muscle-invasive bladder cancer patients?

Yes, adding gemcitabine to cisplatin-based chemotherapy improves survival for muscle-invasive bladder cancer patients, as shown in the NIAGARA trial.

Oncology

Is cisplatin better than carboplatin for surviving advanced bladder cancer?

Yes, cisplatin-based chemotherapy is associated with better overall survival than carboplatin for advanced bladder cancer, but carboplatin is used when patients cannot tolerate…

Oncology

Can a cystic mass in Renal Clear Cell Carcinoma shrink on its own?

Yes, a cystic mass in renal clear cell carcinoma can shrink on its own, but this is extremely rare and does not replace the need for surgical treatment.

Oncology

Does CIK/DC-CIK cell therapy improve survival rates for gastric cancer?

Yes, CIK/DC-CIK cell therapy plus chemotherapy improves overall survival and disease-free survival in gastric cancer patients compared to chemotherapy alone.

Oncology

Does enteral immunonutrition reduce infection risks after gastric cancer surgery?

Yes, enteral immunonutrition (EIN) reduces infection risks after gastric cancer surgery, with a 52% lower odds of infectious complications compared to standard enteral nutrition…

Oncology

Can DNA damage response inhibitors overcome drug resistance in pancreatic cancer?

Yes, DNA damage response inhibitors can help overcome drug resistance in pancreatic cancer, especially when combined with other therapies, but single-agent use has limitations.

Oncology

What environmental factors and genetic risks contribute to the development of pancreatic cancer?

Pancreatic cancer risk comes from modifiable factors like smoking, obesity, and heavy drinking, plus inherited mutations in genes such as BRCA1/2 and PALB2.

Oncology

Is EGCG a potential treatment for digestive system diseases like pancreatic cancer?

EGCG shows promise against pancreatic cancer in lab and animal studies, but human trials are lacking, so it is not yet a proven treatment.

Oncology

Does the protein OTUD7B promote the growth of tumors in pancreatic cancer?

Yes, OTUD7B promotes pancreatic cancer growth by stabilizing oncoproteins and activating signaling pathways like Notch and EGFR/MAPK.

Oncology

How well does osimertinib work for lung cancer patients who have active brain metastasis?

Osimertinib is effective for EGFR-mutated NSCLC patients with active brain metastases, with real-world data showing median progression-free survival of 12.4 months and…

Oncology

Can a high neutrophil-to-lymphocyte ratio predict if a lung cancer patient will develop brain metastasis?

Yes, a high neutrophil-to-lymphocyte ratio (NLR) is linked to a higher risk of developing brain metastasis in lung cancer patients, according to a meta-analysis and other studies.

Oncology

What are the microenvironment mechanisms that drive lung cancer brain metastasis?

Lung cancer brain metastasis is driven by tumor cells co-opting brain developmental pathways, secreting exosomal CEMIP and LCN2, and recruiting astrocytes and macrophages to…

Oncology

Is stereotactic radiotherapy an effective treatment option for patients with brain metastasis?

Yes, stereotactic radiotherapy is an effective treatment for brain metastases, offering high local control rates and preserving cognitive function.

Oncology

What are the risks of brain metastasis in patients diagnosed with lung cancer?

Brain metastases are common in lung cancer, especially small cell (15% at diagnosis) and non-small cell types, with elevated neutrophil-to-lymphocyte ratio as a risk factor…

Oncology

Can a high neutrophil-to-lymphocyte ratio predict if lung cancer will spread to the brain?

Yes, a high neutrophil-to-lymphocyte ratio (NLR) is an independent risk factor for brain metastasis in lung cancer, according to a meta-analysis of 14 studies.

Oncology

Which method is best for placing fiducial markers before radiation for lung cancer?

Endobronchial access has the lowest inaccurate placement rate and low complication risk, making it a strong choice for fiducial marker insertion before lung cancer radiation.

How this works

We pull real patient questions from public Reddit health communities (r/AskDocs, r/diabetes, r/menopause, etc.). Each question is rewritten into a generic medical question (no personal details), then answered by an AI using only cited sources from Vellito's article database and PubMed. A second AI independently scores each answer for accuracy and citation fidelity before publication. Answers below the safety threshold or touching emergency, dosing, or pediatric topics are queued for human review and never auto-published.

This is not medical advice. Always speak with your own doctor before making decisions about your health.